Morningstar

Genmab AS GMAB

Morningstar Rating
Unlock
Stock XCSE Rating as of
DKK 2,257.00 −56.00 (2.42%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Narrow-Moat Genmab's Darzalex Cash Flows Support Growth as Pipeline Advances

Rachel Elfman

Genmab is focused on the development of monoclonal antibody and bispecific antibody therapies in oncology indications. The company's best-known drug, Darzalex (or daratumumab), was developed in partnership with Johnson & Johnson for multiple myeloma. Darzalex is entrenched in multiple myeloma care for several lines of therapy, including the frontline setting. Additionally, Darzalex is often used in combination treatments, unlocking even greater market potential. Genmab receives royalties of up to 20% from J&J on Darzalex sales, plus milestones from the company's antibody platform partnerships.

Read Analysis

Price vs Fair Value

View History
GMAB is trading at a LOCK|<qlVn> premium.
Price
DKK 2,313.00
Fair Value
LOCK|z?
Uncertainty
LOCK|@d#D
1-Star Price
LOCK|@b.r?
5-Star Price
LOCK|^y#
Economic Moat
LOCK|bh!@c
Capital Allocation
LOCK|S$>#j&R

Bulls Say, Bears Say

Bulls

Darzalex is entrenched in the standard of care for multiple myeloma, and it is unlikely any competitors will completely displace it due to its robust efficacy and well-tolerated safety profile.

Bears

Large acquisitions and heavier R&D spending increase financial risk if new drugs fail to meet expectations or achieve meaningful commercial uptake.

Show More

News

View All

Trading Information

Previous Close Price
DKK 2,313.00
Day Range
DKK 2,235.00–2,314.00
52-Week Range
DKK 1,512.00–2,369.00
Bid/Ask
DKK 2,256.00 / DKK 2,259.00
Shares Outstanding
62.41M
Market Cap
DKK 140.85B
Volume/Avg
124,111 / 114,000

Key Statistics

Price/Earnings (Normalized)
21.72
Price/Sales
5.45
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Core
Total Number of Employees
3,119
Website
https://www.genmab.com

Competitors

Valuation

View More
Metric
GMAB
4502
INCY
Price/Earnings (Normalized)
 21.7248.2213.07
Price/Book Value
 3.641.203.71
Price/Sales
 5.451.964.13
Price/Cash Flow
 22.1610.9610.41
Price/Earnings
GMAB
4502
INCY

Financial Strength

Metric
GMAB
4502
INCY
Quick Ratio
 2.440.544.31
Current Ratio
 2.461.144.59
Interest Coverage
 3.880.07791.55
Quick Ratio
GMAB
4502
INCY

Profitability

Metric
GMAB
4502
INCY
Return on Assets (Normalized)
 11.74%5.53%26.83%
Return on Equity (Normalized)
 21.07%11.34%35.48%
Return on Invested Capital (Normalized)
 14.75%7.74%33.21%
Return on Assets
GMAB
4502
INCY

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|Fz?FYXPLOCK|s!R&$128B
 Regeneron Pharmaceuticals Inc
REGN
LOCK|k!#QnqBLOCK|^$%G$76B
 Moderna Inc
MRNA
LOCK|kmn!C#CLOCK|#n$75B
 argenx SE ADR
ARGX
LOCK|zk!yGFMLOCK|w#V$60B
 BeOne Medicines Ltd ADR
ONC
LOCK|>tD$XLQLOCK|$<$44B
 Alnylam Pharmaceuticals Inc
ALNY
LOCK|y?P>T@LOCK|>FKc$31B
 Royalty Pharma PLC Class A
RPRX
LOCK|Ph@pXg&LOCK|bvxG$26B
 BioNTech SE ADR
BNTX
LOCK|?L^DXbLLOCK|nz$24B
 Incyte Corp
INCY
LOCK|Gc>@zKLOCK|Pqp$24B
 Jazz Pharmaceuticals PLC
JAZZ
LOCK|fTDQjbNLOCK|#RW$15B

Sponsor Center